Jennifer Cochran Buys Shares of OmniAb, Inc.
Jennifer Cochran purchased 20,000 shares of OmniAb, Inc. on June 17, 2026.
Key Points
- Jennifer Cochran bought 20,000 shares of OmniAb, Inc. on June 17, 2026, as the stock traded at $2.34.
- OmniAb, Inc. has a market cap of $339 million, a forward P/E of -7.26, and a 52-week range of $1.30 to $2.79.
- Institutional activity includes BlackRock adding 41,900 shares, and Vanguard opening a new position with 3,993,652 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jennifer Cochran, an insider at OmniAb, Inc., purchased 20,000 shares of the company on June 17, 2026. This transaction was not part of a pre-planned trading program. Shares of OmniAb, Inc. (NasdaqGM: OABI) traded near $2.34 on Friday, reflecting ongoing interest in the biotechnology firm.
Insider Buying and Selling at OmniAb, Inc.
In addition to Jennifer Cochran's purchase, other insiders were active on June 17, 2026. Carolyn Bertozzi, another insider, bought 40,000 shares and sold 20,000 shares on the same day. John Higgins also acquired 20,000 shares. These transactions were all made independently of any pre-arranged plans.
Other Institutional Activity in OmniAb, Inc.
Institutional investors have shown varied activity in OmniAb, Inc. BlackRock, Inc. increased its holdings by 41,900 shares, bringing its total to 8,106,881 shares worth approximately $12.7 million. Vanguard Capital Management LLC opened a new position, acquiring 3,993,652 shares valued at about $6.27 million. Geode Capital Management, LLC added 202,887 shares, ending with 2,925,579 shares valued at $4.59 million. Meanwhile, Cadian Capital Management, LP reduced its stake by 277,825 shares, now holding 4,157,129 shares worth around $6.53 million.
OmniAb, Inc. Stock Down 47.7%
On Friday, shares of OmniAb, Inc. traded near $2.34. The company, with a market cap of $339 million, operates in the biotechnology sector. It has a forward P/E ratio of -7.26, indicating it is not currently profitable. The stock's 52-week range is between $1.30 and $2.79, with a 50-day moving average of $1.97 and a 200-day moving average of $1.80. OmniAb maintains a solid financial position with a current ratio of 4.80 and a quick ratio of 4.55.
$OABI stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
OmniAb, Inc. reported revenue of $28.94 million with a modest growth of 2.47%. The company, however, posted a net margin of -187.59% and a return on equity of -20.25%, indicating ongoing challenges in profitability. The next earnings report is scheduled for August 6, 2026.
Analysts Set New Price Targets
Analyst activity includes RBC Capital maintaining a 'buy' rating with a $3.00 price target as of August 7, 2025. Benchmark reiterated its 'buy' rating with a $6.00 target on May 12, 2025. HC Wainwright & Co. reiterated a 'buy' rating with an $11.00 target on March 19, 2025. The consensus among analysts suggests a mean price target of $7.33, based on six analysts' opinions.
About OmniAb, Inc.
OmniAb, Inc. is a biotechnology company based in Emeryville, California. It licenses its discovery research technology to pharmaceutical and biotech firms globally, helping them discover new therapeutics. The company's platform uses transgenic animals and AI tools to create optimized antibodies for drug development. Founded in 2012, OmniAb is led by CEO Matthew W. Foehr and employs 89 people.
Bottom Line
Jennifer Cochran's purchase of OmniAb shares highlights ongoing insider activity at the company. Investors monitor these moves as indicators of potential confidence in the firm's prospects. OmniAb, Inc. remains focused on its biotechnology innovations, although it continues to face profitability challenges. As always, insider trades and institutional activity provide a glimpse into market sentiment, but past actions may not reflect current positions.
Get OmniAb, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OABI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.